文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌随机对照试验中放射治疗报告质量评估

Quality of radiotherapy reporting in randomized controlled trials of prostate cancer.
PubMed 文献 · Radiat Oncol · 2018-06-07

该研究检索1996至2016年MEDLINE收录的前列腺癌随机试验,评估59项含放疗干预臂的试验对10项放疗报告标准的报告充分性,发现报告质量差异显著,靶体积定义、总剂量和分次方案报告充分率97%,危及器官约束、模拟程序和偏差报告充分率仅30%,40%试验充分报告7项以上标准,作者认为需共识指南规范放疗报告。

要点

  • 靶体积定义、总放疗剂量和分次方案在97%的纳入试验中报告充分。
  • 危及器官剂量约束、模拟程序和放疗计划实施偏差在30%的纳入试验中报告充分。
  • 24项试验(40%)充分报告7项及以上标准,发表质量保证结果和协作组试验更可能达到充分报告。

核心结论

  • 前列腺癌随机试验中放疗报告质量存在显著差异,作者认为需要共识指南来标准化随机试验中的放疗报告。

研究设计与样本

  • 检索MEDLINE中1996年至2016年发表、纳入前列腺放疗作为干预臂之一的随机试验,共纳入59项合格试验。
  • 评估10项报告标准是否充分报告:放疗剂量处方方法、放疗剂量计划程序、危及器官剂量约束、靶体积定义、模拟程序、治疗验证程序、总放疗剂量、分次方案、质量保证实施以及放疗计划与实施中偏差的存在与否。
  • 采用多变量逻辑回归分析可能影响报告质量的因素。

主要发现

  • 靶体积定义、总放疗剂量和分次方案在97%的纳入试验中报告充分。
  • 危及器官约束、模拟程序和放疗计划与实施中偏差的存在与否在30%的纳入试验中报告充分。
  • 24项试验(40%)充分报告7项及以上标准。
  • 多变量逻辑分析显示,发表质量保证结果的试验和协作组试验更可能在至少7项标准上具有充分的报告质量。

关键数值与推荐

  • 靶体积定义、总放疗剂量和分次方案报告充分率97%。
  • 危及器官约束、模拟程序和放疗计划与实施偏差报告充分率30%。
  • 24项试验(40%)充分报告7项及以上标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Good radiotherapy reporting in clinical trials of prostate radiotherapy is important because it will allow accurate reproducibility of radiotherapy treatment and minimize treatment variations that can affect patient outcomes. The aim of our study is to assess the quality of prostate radiotherapy (RT) treatment reporting in randomized controlled trials in prostate cancer. METHODS: We searched MEDLINE for randomized trials of prostate cancer, published from 1996 to 2016 and included prostate RT as one of the intervention arms. We assessed if the investigators reported the ten criteria adequately in the trial reports: RT dose prescription method; RT dose-planning procedures; organs at risk (OAR) dose constraints; target volume definition, simulation procedures; treatment verification procedures; total RT dose; fractionation schedule; conduct of quality assurance (QA) as well as presence or absence of deviations in RT treatment planning and delivery. We performed multivariate logistic regression to determine the factors that may influence the quality of reporting. RESULTS: We found 59 eligible trials. There was significant variability in the quality of reporting. Target volume definition, total RT dose and fractionation schedule were reported adequately in 97% of included trials. OAR constraints, simulation procedures and presence or absence of deviations in RT treatment planning and delivery were reported adequately in 30% of included trials. Twenty-four trials (40%) reported seven criteria or more adequately. Multivariable logistic analysis showed that trials that published their quality assurance results and cooperative group trials were more likely to have adequate quality in reporting in at least seven criteria. CONCLUSION: There is significant variability in the quality of reporting on prostate radiotherapy treatment in randomized trials of prostate cancer. We need to have consensus guidelines to standardize the reporting of radiotherapy treatment in randomized trials.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Soon YY, Chen D, Tan TH, et al. Quality of radiotherapy reporting in randomized controlled trials of prostate cancer. Radiat Oncol. 2018. PMID: 29880015. doi:10.1186/s13014-018-1053-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。